Type 2 Diabetes Decompensation as the Clinical Presentation of Thyroid Storm - Cause or Consequence? [0.03%]
甲状腺危象中2型糖尿病失代偿是原因还是结果——临床表现？
Ana Margarida Monteiro,Cláudia Matta-Coelho,Vera Fernandes et al.
Ana Margarida Monteiro et al.
This case study aims to discuss the unusual forms of hyperthyroidism presentation, the nonspecific symptoms and precipitating events. A 70-year-old male was taken to the emergency department for hyperglycaemia, nausea, vomiting and altered ...
Ranibizumab in Diabetic Macular Oedema - A Benefit-risk Analysis of Ranibizumab 0.5 mg PRN Versus Laser Treatment [0.03%]
雷珠单抗治疗糖尿病黄斑水肿——雷珠单抗0.5毫克按需疗法与激光治疗的疗效-风险分析研究
Focke Ziemssen,Alan Cruess,Cornelia Dunger-Baldauf et al.
Focke Ziemssen et al.
Introduction: The structured Benefit-risk Action Team (BRAT) approach aims to assist healthcare decision makers in treatment assessments. We applied BRAT to compare the benefit-risk profile of ranibizumab 0.5 mg versus la...
Sarah L Anderson,Joel C Marrs
Sarah L Anderson
Cardiovascular disease (CVD) remains a leading cause of death in patients with type 2 diabetes (T2D). In addition to glycemic control, a major focus of diabetes treatment involves cardiovascular (CV) risk reduction. In 2008, the US Food and...
An Economic Evaluation of Continuous Glucose Monitoring for People with Type 1 Diabetes and Impaired Awareness of Hypoglycaemia within North West London Clinical Commissioning Groups in England [0.03%]
连续性葡萄糖监测在英国北伦敦地区1型糖尿病伴低血糖症状不明显患者中的经济评价研究
Shraddha Chaugule,Nick Oliver,Brigitte Klinkenbijl et al.
Shraddha Chaugule et al.
To assess the economic impact of providing real time continuous glucose monitoring (CGM) for people with type 1 diabetes (T1D) and impaired awareness of hypoglycaemia (IAH) within North West (NW) London clinical commissioning groups (CCGs)....
Christopher G Parkin,Melissa Holloway,Jeffrey Truesdell et al.
Christopher G Parkin et al.
Introduction: Information about continuous glucose monitoring (CGM) use in the UK is limited. We conducted an online survey of a representative sample of current CGM users in England, Scotland and Wales to address this de...
Continuous Glucose Monitoring Adoption in the United Kingdom - An Economic and Policy Perspective [0.03%]
持续葡萄糖监测在英国的采用情况——经济和政策视角
Nick Oliver
Nick Oliver
Continuous glucose monitoring (CGM) technology provides real-time glucose concentration data to people with diabetes. The data enable timely treatment decisions that can lead to avoidance or mitigation of hypoglycaemia, with potential cost ...
Clinical Safety and Tolerability of Vildagliptin - Insights from Randomised Trials, Observational Studies and Post-marketing Surveillance [0.03%]
维格列汀临床安全性和耐受性：来自随机试验、观察性研究和上市后监测的启示
Chantal Mathieu,Plamen Kozlovski,Päivi M Paldánius et al.
Chantal Mathieu et al.
Vildagliptin is one of the most extensively studied dipeptidyl peptidase-4 (DPP-4) inhibitors in terms of its clinical utility. Over the last decade, a vast panorama of evidence on the benefit-risk profile of vildagliptin has been generated...
Dipeptidyl Peptidase-4 Inhibitor Development and Post-authorisation Programme for Vildagliptin - Clinical Evidence for Optimised Management of Chronic Diseases Beyond Type 2 Diabetes [0.03%]
二肽基肽酶-4抑制剂维格列汀的研发及上市后临床证据：优化2型糖尿病以外的慢性病管理方案
William David Strain,Päivi M Paldánius
William David Strain
The last decade has witnessed the role of dipeptidyl peptidase-4 (DPP-4) inhibitors in producing a conceptual change in early management of type 2 diabetes mellitus (T2DM) by shifting emphasis from a gluco-centric approach to holistically t...
The Vildagliptin Experience - 25 Years Since the Initiation of the Novartis Glucagon-like Peptide-1 Based Therapy Programme and 10 Years Since the First Vildagliptin Registration [0.03%]
维迪西妥单抗经验——诺华 glucagon-like peptide-1 基础治疗项目启动25周年和第一个 vildagliptin 注册10周年
James E Foley,Bo Ahrén
James E Foley
The discovery of the incretin hormone glucagon like peptide-1 (GLP-1), and its usefulness in the treatment of type 2 diabetes mellitus (T2DM) followed by the finding that dipeptidyl peptidase-4 (DPP-4) inhibition prevents GLP-1 inactivation...
Stefano Del Prato
Stefano Del Prato
After many years of limited therapeutic opportunities, the treatment of type 2 diabetes has become more target and pathophysiologically driven. A typical example is represented by the development of the dipeptidyl peptidase-4 (DPP-4) inhibi...